{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T04:01:51Z","timestamp":1760241711902,"version":"build-2065373602"},"reference-count":32,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2018,7,12]],"date-time":"2018-07-12T00:00:00Z","timestamp":1531353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81172980"],"award-info":[{"award-number":["81172980"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"State Project For Essential Drug Research and Development","award":["2016ZX09J16101"],"award-info":[{"award-number":["2016ZX09J16101"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>Anthrax caused by Bacillus anthracis is a lethal infectious disease, especially when inhaled, and the mortality rate approaches 100% without treatment. The anthrax antitoxin monoclonal antibody (MAb) 5E11 is a humanized antibody that targets the anthrax protective antigen (PA). The efficacy of 5E11 needs proper animal models. However, anthrax spores are extremely dangerous, so experiments must be conducted under Biosafety Level 3 conditions. Considering the critical effects of lethal toxin (LT) on hosts during infection, we report the establishment of a LT-challenged rabbit model, which caused 100% mortality with a dose of 2 mg PA + 1 mg LF, while a 4 mg PA + 2 mg LF challenge could limit death to within three days. Then, we evaluated 5E11 efficacy against LT. A prophylactic study showed that the i.v. administration of 40 mg\/kg 5E11 four days before lethal dose LT challenge could lead to 100% survival. In therapeutic studies, the i.v. administration of 40 mg\/kg 5E11 10 min after lethal dose LT challenge could provide complete protection. Overall, we developed a new LT-challenged rabbit model, and our results indicate that 5E11 shows potential for the clinical application in anthrax treatment.<\/jats:p>","DOI":"10.3390\/toxins10070289","type":"journal-article","created":{"date-parts":[[2018,7,12]],"date-time":"2018-07-12T11:19:24Z","timestamp":1531394364000},"page":"289","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Establishment of a New Zealand White Rabbit Model for Lethal Toxin (LT) Challenge and Efficacy of Monoclonal Antibody 5E11 in the LT-Challenged Rabbit Model"],"prefix":"10.3390","volume":"10","author":[{"given":"Duanyang","family":"Zhang","sequence":"first","affiliation":[{"name":"Laboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, 20 Dongdajie Street, Fengtai District, Beijing 100071, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weicen","family":"Liu","sequence":"additional","affiliation":[{"name":"Laboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, 20 Dongdajie Street, Fengtai District, Beijing 100071, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhonghua","family":"Wen","sequence":"additional","affiliation":[{"name":"Laboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, 20 Dongdajie Street, Fengtai District, Beijing 100071, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Li","sequence":"additional","affiliation":[{"name":"Laboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, 20 Dongdajie Street, Fengtai District, Beijing 100071, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuling","family":"Liu","sequence":"additional","affiliation":[{"name":"Laboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, 20 Dongdajie Street, Fengtai District, Beijing 100071, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianmin","family":"Li","sequence":"additional","affiliation":[{"name":"Laboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, 20 Dongdajie Street, Fengtai District, Beijing 100071, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[{"name":"Laboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, 20 Dongdajie Street, Fengtai District, Beijing 100071, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2018,7,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1007\/s00134-012-2541-0","article-title":"An overview of anthrax infection including the recently identified form of disease in injection drug users","volume":"38","author":"Hicks","year":"2012","journal-title":"Intensive Care Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1111\/j.1365-2958.2006.05179.x","article-title":"Poly-gamma-glutamate in bacteria","volume":"60","author":"Candela","year":"2006","journal-title":"Mol. Microbiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/sj.emboj.7600495","article-title":"Capsule synthesis by Bacillus anthracis is required for dissemination in murine inhalation anthrax","volume":"24","author":"Drysdale","year":"2005","journal-title":"EMBO J."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Head, B.M., Rubinstein, E., and Meyers, A.F. (2016). Alternative pre-approved and novel therapies for the treatment of anthrax. BMC Infect. Dis, 16.","DOI":"10.1186\/s12879-016-1951-y"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1056\/NEJM199909093411107","article-title":"Anthrax","volume":"341","author":"Dixon","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.mam.2009.06.002","article-title":"Anthrax toxins: A weapon to systematically dismantle the host immune defenses","volume":"30","author":"Tournier","year":"2009","journal-title":"Mol. Asp. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.mam.2009.07.003","article-title":"Cellular and systemic effects of anthrax lethal toxin and edema toxin","volume":"30","author":"Moayeri","year":"2009","journal-title":"Mol. Asp. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.3390\/toxins3081004","article-title":"Monoclonal antibody therapies against anthrax","volume":"3","author":"Chen","year":"2011","journal-title":"Toxins"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1128\/CVI.00099-13","article-title":"Evaluation of immunogenicity and efficacy of anthrax vaccine adsorbed for postexposure prophylaxis","volume":"20","author":"Ionin","year":"2013","journal-title":"Clin. Vaccine Immunol. CVI"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/jac\/dkh258","article-title":"Selection of Bacillus anthracis isolates resistant to antibiotics","volume":"54","author":"Athamna","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1128\/AAC.47.7.2362-2365.2003","article-title":"In vitro selection and characterization of Bacillus anthracis mutants with high-level resistance to ciprofloxacin","volume":"47","author":"Price","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1146\/annurev-micro-091014-104523","article-title":"Anthrax pathogenesis","volume":"69","author":"Moayeri","year":"2015","journal-title":"Annu Rev. Microbiol."},{"key":"ref_13","unstructured":"Chen, W., Li, J., Li, B., Zhang, J., Hou, L., Song, X., Yu, T., Xu, J., Fu, L., and Zhang, J. (2012). A Monoclonal Antibody That Neutralize Anthrax Protective Antigen (PA) Toxin and Its Application. (ZL201210361845.4), Patent."},{"key":"ref_14","first-page":"982","article-title":"The pathology of experimental anthrax in rabbits exposed by inhalation and subcutaneous inoculation","volume":"122","author":"Zaucha","year":"1998","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1128\/IAI.74.2.1016-1024.2006","article-title":"Human monoclonal anti-protective antigen antibody completely protects rabbits and is synergistic with ciprofloxacin in protecting mice and guinea pigs against inhalation anthrax","volume":"74","author":"Peterson","year":"2006","journal-title":"Infect. Immun."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1056\/NEJMoa0810603","article-title":"Raxibacumab for the treatment of inhalational anthrax","volume":"361","author":"Migone","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1128\/AAC.04593-14","article-title":"Efficacy of ETI-204 monoclonal antibody as an adjunct therapy in a New Zealand white rabbit partial survival model for inhalational anthrax","volume":"59","author":"Biron","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5787","DOI":"10.1128\/AAC.00972-16","article-title":"Efficacy projection of obiltoxaximab for treatment of inhalational anthrax across a range of disease severity","volume":"60","author":"Yamamoto","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5796","DOI":"10.1128\/AAC.01102-16","article-title":"Obiltoxaximab prevents disseminated Bacillus anthracis infection and improves survival during pre- and postexposure prophylaxis in animal models of inhalational anthrax","volume":"60","author":"Yamamoto","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Xu, W., Ohanjandian, L., Sun, J., Cui, X., Suffredini, D., Yan, L., Welsh, J., and Eichacker, P.Q. (2017). A systematic review and meta-analysis of preclinical trials testing anti-toxin therapies for B. anthracis infection: A need for more robust study designs and results. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0182879"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1128\/CVI.00292-12","article-title":"Characterization of a therapeutic model of inhalational anthrax using an increase in body temperature in New Zealand white rabbits as a trigger for treatment","volume":"19","author":"Comer","year":"2012","journal-title":"Clin. Vaccine Immunol. CVI"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1128\/AAC.02295-13","article-title":"Efficacy and safety of AVP-21D9, an anthrax monoclonal antibody, in animal models and humans","volume":"58","author":"Malkevich","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5684","DOI":"10.1128\/AAC.00458-13","article-title":"Evaluation of intravenous anthrax immune globulin for treatment of inhalation anthrax","volume":"57","author":"Mytle","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.4049\/jimmunol.1002471","article-title":"Neutrophil elastase mediates pathogenic effects of anthrax lethal toxin in the murine intestinal tract","volume":"185","author":"Fang","year":"2010","journal-title":"J. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1128\/IAI.00963-10","article-title":"Myd88-dependent signaling protects against anthrax lethal toxin-induced impairment of intestinal barrier function","volume":"79","author":"Shu","year":"2011","journal-title":"Infect. Immun."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3390\/toxins3060591","article-title":"The effects of anthrax lethal toxin on host barrier function","volume":"3","author":"Xie","year":"2011","journal-title":"Toxins"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Chen, S., Hui, F., Tao, X., Auth, R.D., Patel, N., Murray, P.R., Snoy, P.J., and Frucht, D.M. (2012). Anthrax lethal toxin disrupts intestinal barrier function and causes systemic infections with enteric bacteria. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0033583"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"6584","DOI":"10.1074\/jbc.M114.627943","article-title":"A heterodimer of a VHH (variable domains of camelid heavy chain-only) antibody that inhibits anthrax toxin cell binding linked to a VHH antibody that blocks oligomer formation is highly protective in an anthrax spore challenge model","volume":"290","author":"Moayeri","year":"2015","journal-title":"J. Biol. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3390\/toxins5010120","article-title":"Bacillus anthracis protective antigen kinetics in inhalation spore-challenged untreated or levofloxacin\/raxibacumab-treated New Zealand white rabbits","volume":"5","author":"Corey","year":"2013","journal-title":"Toxins"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1128\/AAC.01689-10","article-title":"Antibiotics cure anthrax in animal models","volume":"55","author":"Weiss","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1089\/hs.2015.0032","article-title":"Antitoxin treatment of inhalation anthrax: A systematic review","volume":"13","author":"Huang","year":"2015","journal-title":"Health Secur."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.pep.2013.02.012","article-title":"Secretory expression and efficient purification of recombinant anthrax toxin lethal factor with full biological activity in E. coli","volume":"89","author":"Liu","year":"2013","journal-title":"Protein Expr. Purif."}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/10\/7\/289\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:11:53Z","timestamp":1760195513000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/10\/7\/289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,12]]},"references-count":32,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2018,7]]}},"alternative-id":["toxins10070289"],"URL":"https:\/\/doi.org\/10.3390\/toxins10070289","relation":{},"ISSN":["2072-6651"],"issn-type":[{"type":"electronic","value":"2072-6651"}],"subject":[],"published":{"date-parts":[[2018,7,12]]}}}